ArticleClinical nuclear medicine2025
The Characteristics of Prostate Mucinous Adenocarcinoma Visualized by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
Article in Clinical nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary prostate mucinous adenocarcinoma is an exceedingly rare entity with distinct imaging characteristics. We report the case of a 62-year-old man with biopsy-proven prostate mucinous adenocarcinoma. The patient underwent MRI and multi-tracer PET/CT. PET/CT images demonstrated the prostate lesion with moderate uptake of 68 Ga-PSMA and 68 Ga-FAPI, yet significantly high 18 F-FDG uptake. No abnormal radiotracers' uptake was observed elsewhere in the body. Multi-tracer PET/CT findings suggest that 18 F-FDG may be a more suitable radiotracer for the systemic assessment of primary prostate mucinous adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.